We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 26, 2022

Vistusertib Plus Anastrozole in Patients With HR+ Recurrent or Metastatic Endometrial Cancer

JAMA Oncology


Additional Info

JAMA Oncology
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial
JAMA Oncol 2022 May 12;[EPub Ahead of Print], P Heudel, JS Frenel, C Dalban, F Bazan, F Joly, A Arnaud, C Abdeddaim, A Chevalier-Place, P Augereau, P Pautier, C Chakiba, B You, L Lancry-Lecomte, G Garin, V Marcel, JJ Diaz, I Treilleux, D Pérol, M Fabbro, I Ray-Coquard

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading